Looking for a Growth Stock? Why It is Time to Focus on Sequenom (SQNM) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:39AM CDT
Sequenom (SQNM) seems well-positioned for future earnings growth and has double digit earnings growth prospect as it sees rising earnings estimates, coupled with a solid Zacks Rank.
Investors are betting against Sequenom (SQNM), Should You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 08, 8:21AM CDT
Investors are betting against Sequenom (SQNM), Should You?
Analysis of Automated Microbiology Instrumentation and Strategic Profiles of Leading Suppliers
M2 - Wed May 07, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c9zbx3/analysis_of) has announced the addition of the "Analysis of Automated Microbiology Instrumentation and Strategic Profiles of Leading Suppliers" report to their offering. This new 148-page report reviews current instrumentation technologies, and profiles features of leading automated and semi-automated Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic analyzers. The report also presents strategic assessments of current and emerging suppliers of microbiology products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests. The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon. Key Topics Covered: Introduction 1. Major Factors Affecting Market Penetration of Microbiology Instrumentation 2. Traditional Practices 3. Technological Challenges 4. Automation: Impact on the Microbiology Laboratory and the Patient Major Microbiology Automated and Semiautomated Systems 1. Multiple Purpose Microbiology Systems 2. Specialized Microbiology Systems 3. Molecular Diagnostic Systems 4. Immunodiagnostic Systems Companies Mentioned: - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca/Nuvelo - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - Biokit - Biotest - Caliper - Cepheid - Decode - DiaSorin - Diadexus - Diamedix - Eiken Chemical - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Hologic/Gen-Probe - ID Biomedical/GSK - Illumina - Kreatech - Li-Cor Biosciences - Life Technology - Lonza - Monogram Biosciences - Myriad Genetics - Nanogen/Elitech - Novartis Diagnostics/Grifols - Orchid CellMark - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - SeraCare - Shimadzu - Siemens - Sierra Molecular - Takara Bio - Tecan - Thermo Fisher - Wako - Wallac/PE - bioMerieux For more information visit http://www.researchandmarkets.com/research/c9...nalysis_of
Enteric Diseases in Germany 2014: Market Outlook and Emerging Opportunities
M2 - Wed May 07, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwhxpk/enteric_diseases) has announced the addition of the "Enteric Diseases in Germany 2014: Market Outlook and Emerging Opportunities" report to their offering. This new 322-page report presents detailed analysis of the German Enteric Diseases market, including sales forecasts and supplier shares for Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, Vibrio and Yersinia. The report provides test volume and sales projections for Hospitals and Commercial/Private Labs. In addition to market share and sales forecasts, the report: - Examines market applications of Molecular Diagnostics, Monoclonal Antibodies, Immunoassays, IT and other emerging technologies; - Reviews features and operating characteristics of major analyzers used for microbiology testing; - Profiles key suppliers and potential market entrants developing innovative technologies and products; and - Analyzes emerging opportunities, alternative market penetration strategies, market entry barriers/risks, and strategic planning issues. Methodology The report is based on a combination of primary and secondary information sources, including interviews with laboratory directors, and executives of leading diagnostics companies and start-up firms developing innovative products. In addition to primary sources of information, a comprehensive review of the most recent technical and business publications, manufacturer product and financial literature, as well as the author's proprietary data files was conducted. Key Topics Covered: I. Introduction II. Worldwide Market and Technology Overview A. Major Infectious Disease Tests B. Instrumentation Review of Leading Analyzers Marketed By Abbott, Beckman Coulter/Danaher, BioMerieux, OrthoClinical Diagnostics, Roche, Siemens, Tosoh, Wallac and Other Suppliers C. Emerging Diagnostic Technologies III. Germany: Market Size, Growth and Major Suppliers' Sales and Market Shares Alternative Market Penetration Strategies A. Internal Development B. Collaborative Arrangements C. University Contracts D. Distribution Strategies for Decentralized Testing Markets Potential Market Entry Barriers and Risks A. Market Maturity B. Cost Containment C. Competition D. Technological Edge and Limitations E. Patent Protection F. Regulatory Constraints G. Decentralized Testing Market Challenges Competitive Assessments: - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - BioRad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Enzo Biochem - Fujirebio - GenProbe - Hologic - ID Biomedical Innogenetics/Solvay - Kreatech - Life Technology - Lonza - Nanogen/Elitech - Novartis Diagnostics - OrthoClinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher - Wallac - Wako For more information visit http://www.researchandmarkets.com/research/mw...c_diseases
Will Sequenom (SQNM) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:20AM CDT
Will Sequenom (SQNM) Continue to Surge Higher?
Sequenom Inc. (SQNM) in Focus: Stock Rallies 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 05, 7:44AM CDT
Sequenom Inc. (SQNM) was a big mover last session, as the company saw its shares rally nearly 9.00% on the day.
Why DigitalGlobe, Wynn Resorts, and Sequenom Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 02, 7:05PM CDT
The stock market closed the week on a sour note, as investors ignored larger than expected gains in April U.S. nonfarm payrolls and instead focused on the potential geopolitical fallout from rising tensions in Ukraine. Yet even though violence in the...
Why Sequenom, Inc. Shares Took Flight
Sean Williams, The Motley Fool - Motley Fool - Fri May 02, 12:55PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sequenom , a developer of genomic and...
Why Sequenom (SQNM) Stock is Up Today
at The Street - Fri May 02, 11:02AM CDT
Sequenom (SQNM) rose Friday after the DNA massarray manufacturer reported first-quarter earnings that edged analysts' expectations.
Hot Stock: Sequenom, Shares Gain 11.6% (SQNM)
Comtex SmarTrend(R) - Fri May 02, 10:11AM CDT
Sequenom (NASDAQ:SQNM) is one of today's best performing low-priced stocks, up 11.6% to $2.98 on 1.7x average daily volume. Thus far today, Sequenom has traded 3.2 million shares, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (11.6% to the Dow's -0.2%) and outperformed the S&P 500 (11.6% to the S&P's -0.1%) during today's trading.
Sequenom, Inc. Reports Financial Results For The First Quarter Of 2014
PR Newswire - Thu May 01, 3:10PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported record revenue of $46.3 million for the first quarter of 2014, an increase of 20% compared to revenue of $38.5 million for the first quarter of 2013. First quarter 2014 revenues from diagnostic services grew 27% compared to the first quarter of 2013, and 13% on a sequential basis over the fourth quarter of 2013.
Top Gainers Technical Data -- Research on Wolverine World Wide, MagneGas, Sequenom, and Cubist Pharma
PR Newswire - Thu May 01, 3:22AM CDT
On Tuesday, April 29, 2014, the NASDAQ Composite ended at 4,103.54, up 0.72%, the Dow Jones Industrial Average advanced 0.53%, to finish the day at 16,535.37, and the S&P 500 closed at 1,878.33, up 0.48%. The session saw a positive impact from Financials, Information Technology, and Materials sectors along with a drag from Utilities and Consumer Staples sectors. A number of stocks saw large movements, including Wolverine World Wide Inc. (NYSE: WWW), MagneGas Corp. (NASDAQ: MNGA), Sequenom Inc. (NASDAQ: SQNM) and Cubist Pharmaceuticals Inc. (NASDAQ: CBST). Free technical research on WWW, MNGA, SQNM and CBST can be downloaded upon signing up at:
Research and Markets: US Prenatal Testing Market 2014-2018: PerkinElmer Inc., Quest Diagnostics Inc., Sequenom Inc., and Verinata Health Dominate the Industry
Business Wire - Wed Apr 30, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6zm2d3/prenatal_testing) has announced the addition of the "US Prenatal Testing Market 2014-2018: PerkinElmer Inc., Quest Diagnostics Inc., Sequenom Inc., and Verinata Health Dominate the Industry" report to their offering.
US Prenatal Testing Market 2014-2018: PerkinElmer Inc., Quest Diagnostics Inc., Sequenom Inc., and Verinata Health Dominate the Industry
M2 - Wed Apr 30, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7lqfr2/prenatal_testing) has announced the addition of the "US Prenatal Testing Market 2014-2018: PerkinElmer Inc., Quest Diagnostics Inc., Sequenom Inc., and Verinata Health Dominate the Industry" report to their offering. The Prenatal Testing market in the US is experiencing a significant increase in the number of new tests being launched in the market. For instance, Sequenom launched Laboratoire Cerba's non-invasive prenatal test in San Diego, California, and Saint-Ouen-L'Aum?ne, France, in December 2013 and enhanced the sequencing series for its MaterniT21 PLUS laboratory-developed test in October 2013. Moreover, PerkinElmer Inc. expanded its prenatal screening test offerings, introducing the first early onset preeclampsia screening test in the US in August 2013. This trend will have a positive impact on the growth of the market. According to the report, one of the major factors driving the market is the increase in the incidence of fetal abnormalities such as Down syndrome, Edwards syndrome, neural tube defects, and genetic defects and disorders such as sickle cell anemia, thalassemia, spina bifida, Tay Sachs disease, cystic fibrosis, muscular dystrophy, cleft palate, and fragile X syndrome. Further, the report states that one of the major challenges is the decline in fertility rates all over the world. The decline in the fertility rate will lead to a decline in pregnancies, which in turn will lead to a reduction in the demand for prenatal testing during the forecast period. Key vendors dominating this space are: - PerkinElmer Inc - Quest Diagnostics Inc. - Sequenom Inc. - Verinata Health Inc. Other vendors mentioned in the report are: - ANGLE plc - Ariosa Diagnostics Inc - BGI Health - CellScape Corp - Fluidigm Corp. - Ikonisys Inc - Kellbenx Inc - Natera Inc - Ravgen Inc. - Trovagene Inc. For more information visit http://www.researchandmarkets.com/research/7l...al_testing
Sequenom, Inc. Announces Date Of First Quarter 2014 Financial Results And Conference Call
PR Newswire - Thu Apr 17, 6:00AM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced it will report financial results for the first quarter of 2014 after closing of the NASDAQ Global Market on Thursday, May 1, 2014.
Could A Nasdaq Correction Benefit These 8 Value Stocks?
at The Street - Wed Apr 16, 4:34PM CDT
a����James Dennin, Kapitall: Value investors pick up shares during market corrections. Could Nasdaq's performance benefit these 9 value stocks? Everyone's [...]
Global SNP Genotyping and Analysis Market Forecasts & Opportunities 2013-2019
M2 - Mon Apr 14, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bk2mlx/snp_genotyping) has announced the addition of the "Global SNP Genotyping and Analysis Market Forecasts & Opportunities 2013-2019" report to their offering. The global market is expected to reach USD 9,485.2 million by 2019, up from USD 2,385.2 million in 2012, growing at a CAGR of 21.8% The study elucidates the market dynamics, which are the drivers, restraints and opportunities that a market player will come across in this area. It gives a brief introduction to each topic as it covers the commercial aspects of the market and its technologies along with current trends. The report analyzes four major applications of SNP genotyping in Life Sciences and Healthcare industry which are Pharmaceutical/Pharmacogenomics, Diagnostics, Agricultural Biotechnology and Breeding and Animal Livestock. The market products are internally affected by power of substitution since there are around 8 to 10 different efficient techniques to carry out SNP genotyping such as TaqMan, SNPlex, Microarray, MALDI-TOF etc. With the completion of the Human Genome Project, over 2 million SNP's have been added to global databases which in turn have initiated a series of research and development projects to understand potential of developing diagnostic tests through rapid genotyping techniques. A considerable amount of revenue is spent on research to developing diagnostic products similar to companion diagnostics which would enable to give us a preview of how a genome would unfold as an individual grows older. There is a high intensity of research in food crops such as rice, wheat, oats, corn, maize and other grasses. SNP genotyping in agriculture gained acceptance long before other applications. The GeneChip Rice 44K array offered by Affymetrix is one of the most popular platforms for rice genotyping which identifies variants that impact yield. Fluidigm's SNPtype assays have been utilized by International Rice Research Institute which holds the world's largest ex-situ collection of rice germplasm and plays a very large role in maintaining this repository. Scope of the Report Technology - SNP GeneChips and Microarrays - Taqman Allelic Discrimination - SNP by Pyrosequencing - AB SNPlex - MassARRAY MALDI-TOF - Others Application - Pharmaceuticals and Pharmacogenomics - Diagnostic Research - Agricultural Biotechnology - Breeding and Animal Livestock Key Topics Covered: - Introduction - Executive Summary - Market Overview: Global SNP Genotyping & Analysis Market - Global SNP Genotyping & Analysis Market, by Technologies, 2011 - 2019 (USD Million) - Global SNP Genotyping and Analysis Market, by Applications, 2011 - 2019 (USD Million) - Global SNP Genotyping and Analysis Market, by Geography, 2011 - 2019 (USD Million) - Competitive Landscape - Company Profiles - Affymetrix, Inc - Douglas Scientific LLC - Fluidigm - Illumina, Inc - Life Technologies Corporation - PREMIER Biosoft - Sequenom, Inc - ThermoFisher Scientific Visit http://www.researchandmarkets.com/research/bk...genotyping
Prenatal and New-born Genetic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 27, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r4qf5z/prenatal_and) has announced the addition of the "Prenatal and New-born Genetic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Prenatal testing and diagnosis have enabled the detection of certain genetic abnormalities in as early as 8 to 10 weeks of gestation and also helps to determine the sex of the fetus. Prenatal and newborn genetic testing is referred to as the utilization of screening/diagnostic procedures for a fetus or a new born baby to detect chromosomal abnormalities such as Down syndrome, Patau syndrome and Edward syndrome. This report studies the global prenatal and newborn genetic testing market from two perspectives namely, types of technologies and the major geographic markets. The global prenatal and newborn genetic testing market by technology has been segmented as diagnostic technique and screening methods. Diagnostic technique is further classified as polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH) and array-comparative genomic hybridization (aCGH). Similarly, screening methods are further categorized as non-invasive prenatal tests and maternal serum screening. Key Topics Covered: Introduction Executive Summary Prenatal and Newborn Genetic Testing Market Overview Prenatal and Newborn Genetic Testing Market, by Technology Prenatal and Newborn Genetic Testing Market, by Geography Competitive Landscape Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Agilent Technologies, Inc. - Ariosa Diagnostics, Inc. - Bio-Rad Laboratories, Inc. - Illumina, Inc. - Laboratory Corporation of America Holdings (LabCorp) - Natera, Inc. - PerkinElmer, Inc. - Sequenom, Inc. For more information visit http://www.researchandmarkets.com/research/r4...enatal_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Sequenom and Former CFO Resolve Litigation
PR Newswire - Fri Mar 21, 4:00PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced a resolution of litigation between the Company and Paul Hawran. Mr. Hawran served as the Company's Chief Financial Officer from April 2007 until September 2009. Mr. Hawran resigned in September 2009.
Sequenom (SQNM) Soars: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:51AM CDT
Sequenom Inc. was a big mover last session, as its shares rose over 6% on the day.